What the FDA labels say about taking them together
Erythromycin and nifedipine
Nifedipine's FDA label of December 24, 2024 names erythromycin in its drug interactions section; erythromycin's label does not name nifedipine itself but warns about its class (Calcium channel blockers (dihydropyridines)). The nifedipine label: “CYP3A inhibitors such as fluconazole, itraconazole, clarithromycin, erythromycin, nefazodone, fluoxetine, saquinavir, indinavir, and nelfinavir may result in increased exposure to nifedipine when co-administered.”
Check it at the source: the erythromycin FDA label on DailyMed (effective August 1, 2024, Teva Pharmaceuticals USA, Inc.); the nifedipine FDA label on DailyMed (effective December 24, 2024, Aurobindo Pharma Limited).
What does the erythromycin label say about nifedipine?
Erythromycin's label does not name nifedipine itself; it warns about its class (Calcium channel blockers (dihydropyridines)):
Erythromycin label, drug interactionsHypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.
Erythromycin label, warningsThese include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see PRECAUTIONS - Drug Interactions ).
Source: FDA drug label (Erythromycin), Teva Pharmaceuticals USA, Inc., effective August 1, 2024 (SPL set 75a0bd5a-d09f-483b-bfd8-f8343b149eb2), via openFDA; the full label on DailyMed
What does the nifedipine label say about erythromycin?
Nifedipine label, drug interactionsCYP3A inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when co-administered.
Procardia Xl label (Pfizer Laboratories Div Pfizer Inc, December 16, 2025), drug interactionsCYP3A inhibitors such as fluconazole, itraconazole, clarithromycin, erythromycin, nefazodone, fluoxetine, saquinavir, indinavir, and nelfinavir may result in increased exposure to nifedipine when co-administered.
Source: FDA drug label (Procardia Xl, NDA019684), Pfizer Laboratories Div Pfizer Inc, effective December 16, 2025 (SPL set 8ebcb33c-f43b-4b36-9f94-9774b2a59e06), via openFDA
Source: FDA drug label (Nifedipine), Aurobindo Pharma Limited, effective December 24, 2024 (SPL set eb70b7ff-f9f0-41d0-901a-f4c04ae9ed46), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Erythromycin | Nifedipine | |
|---|---|---|
| Labeled for | Bacterial infections, Acne | High blood pressure, Angina |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.96 per tablet 250 mg tablet | $0.130 per tablet 30 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once